MC
TMBR

Moors & Cabot’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

Moors & Cabot’s Portfolio TMBR Stock Details TMBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3
Closed -$19K – 556
2017
Q2 		$19K Buy
3
+2
+200% +$17.4K ﹤0.01% 506
2017
Q1 		$7K Buy
+1
New +$6.92K ﹤0.01% 515

Other funds holding TMBR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

Moors & Cabot's TMBR Position: Q3 2017 in Review

Moors & Cabot sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q3 2017, closing a stake of 3 shares — an estimated $19K sold.

Moors & Cabot first reported a position in TMBR in Q1 2017 and held it in 2 quarters. The position peaked at $19K in Q2 2017. 18 funds tracked by Wall St. Rank hold TMBR as of Q3 2017.

  • Moors & Cabot reported no remaining Timber Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Moors & Cabot sold 3 Timber Pharmaceuticals, Inc. shares in Q3 2017, an estimated $19K.
  • Moors & Cabot first reported a position in Timber Pharmaceuticals, Inc. in Q1 2017 and held it in 2 quarters.
  • Moors & Cabot's Timber Pharmaceuticals, Inc. position peaked at $19K in Q2 2017.
  • 18 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q3 2017.

Based on Moors & Cabot's 13F filing for Q3 2017, filed 16 Nov 2017.